Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®

Reuters

Sep 12

Uni-Bio Science Group and <a href="https://laohu8.com/S/688136">Kexing Biopharm</a> Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®

Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai®, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2196916_en), on September 12, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2566218927"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2566218927\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2566218927?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 17:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566218927","market":"us","top_or_hot":-1,"title":"Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Uni-Bio Science Group and <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai®, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2196916_en), on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 17:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Uni-Bio Science Group and <a href=\"https://laohu8.com/S/688136\">Kexing Biopharm</a> Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai®, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2196916_en), on September 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250912:nNDL95x3Vt:1","article_id":"2566218927","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566218927","pubTimestamp":1757669282,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai  in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688136":"科兴制药","BK1161":"生物科技","00690":"联康生物科技集团","BK0239":"医药制造"},"translate_title":"Uni-Bio Science Group与科兴生物制药结成战略联盟，全球化骨质疏松症治疗博古泰®","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688136":0.9,"00690":0.9},"content_text":"Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®\n    \n\n        Uni-Bio Science Group Ltd. has announced a strategic cooperation agreement with Kexing Biopharm, granting them exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico. This collaboration aims to expand the global reach of Bogutai®, an innovative osteoporosis treatment, with expectations to complete registration and generate revenue by the end of 2026. By leveraging Kexing Biopharm's extensive international commercialization network and expertise in regulatory approvals, the partnership intends to accelerate the product's registration and commercialization process, ultimately enhancing global competitiveness in osteoporosis care.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Uni-Bio Science Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2196916_en), on September 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}